Taken together, SIRP-β2 is broadly expressed in AML patients and high expression of SIRP-β2 independently associates with favourable OS and EFS independent of the ELN intermediate risk group and FAB classification. The gene discussed is SIRPB2; the disease is acute myeloid leukemia.